| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.001 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.15 | 0.001 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.001 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.12 | 0.004 |